IEX •
Healthcare •
Biotechnology •
Quote as of 09/11/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization14.81 mln
Earnings Date11/11/2026
EPS
130
Exceptional
P / E
0.07
Anomalous
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
75.00
Transformational upside
Relative Strength
98
/ 100
Top performer
ROE
-96.15
Deeply negative
Business Description
GT Biopharma Inc. is a San Francisco-based clinical-stage company focused on developing cancer and autoimmune treatments using its proprietary immune cell-engaging technology. The company currently has two cancer therapies in Phase 1 clinical trials ? one targeting blood cancers and another targeting solid tumors ? along with an early-stage treatment for lupus and related autoimmune conditions. Originally founded in 1965 under the name OXIS International Inc., the company rebranded to GT Biopharma in 2017.
